From the FDA Drug Label
Estradiol valerate injection, USP is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
The drug Delestrogen is another name for estradiol valerate (IM). Estradiol valerate (IM) is used to treat:
- Moderate to severe vasomotor symptoms associated with menopause
- Moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause
- Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
- Advanced androgen-dependent carcinoma of the prostate (for palliation only) 1
From the Research
Delestrogen should be used for hormone replacement therapy in postmenopausal women to prevent osteoporosis and alleviate menopausal symptoms, as supported by the most recent and highest quality study 2. Delestrogen is a brand name for estradiol valerate, a form of estrogen hormone used primarily for hormone replacement therapy. It's administered as an intramuscular injection, typically in doses ranging from 10-40 mg every 1-2 weeks, depending on the condition being treated.
Key Points to Consider
- Delestrogen is commonly prescribed for menopausal symptom relief, hormone therapy for transgender women, and treatment of certain hormonal deficiencies.
- The medication works by supplementing or replacing the body's natural estrogen, which helps manage symptoms like hot flashes, vaginal dryness, and bone loss in menopausal women.
- For transgender women, it promotes feminizing effects including breast development and fat redistribution.
- Side effects may include nausea, headaches, breast tenderness, and fluid retention.
- More serious risks include blood clots, stroke, and certain cancers, so regular medical monitoring is essential.
- Patients should follow their healthcare provider's specific dosing instructions and report any unusual symptoms promptly.
Evidence-Based Recommendations
- According to the study published in 2023 2, hormone replacement therapy (HRT) is a cost-effective therapy in the early postmenopause, especially in symptomatic women at risk for osteoporosis, unless contraindicated.
- The study also suggests that HRT prevents all osteoporotic fractures, even in low-risk populations, and that the bone protective effect lasts while on HRT.
- Another study published in 2022 3 highlights the importance of estrogen in maintaining bone health and preventing osteoporosis, and suggests that estrogen replacement therapy is an effective treatment for estrogen deficiency-related osteoporosis.